Trastuzumab for early breast cancer [2]

Lancet

Volumn 367, Issue 9505, 2006, Pages 107-108

  Stuart, N S A ^a   Bishop, Jill ^b   Bale, Catherine ^c  

^a BANGOR UNIVERSITY   (United Kingdom)

^b GLAN CLWYD HOSPITAL   (United Kingdom)

^c YSBYTY GWYNEDD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; BREAST METASTASIS; CANCER RISK; CLINICAL TRIAL; DRUG EFFECT; EARLY CANCER; HUMAN; LETTER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; TREATMENT OUTCOME; BREAST TUMOR; DRUG APPROVAL; FEMALE; NOTE; REPRODUCIBILITY; TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; DRUG APPROVAL; FEMALE; HUMANS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 30444434060     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)67952-X     Document Type: Letter

References (1)

1. The Lancet Herceptin and early breast cancer: a moment for caution Lancet 366 2005 1673